Which cardiovascular conditions contraindicate NeoRecormon (epoetin beta) when used to increase autologous blood yield?

NeoRecormon (epoetin beta) is contraindicated for increasing autologous blood yield in patients with poorly controlled hypertension, myocardial infarction or stroke in the month preceding treatment, unstable angina pectoris, or increased risk of deep venous thrombosis, such as a history of venous thromboembolic disease.